Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Canada
  4. CANADIAN NATIONAL STOCK EXCHANGE
  5. MYND Lifesciencs Inc.
  6. News
  7. Summary
    MYND   CA62857B1094

MYND LIFESCIENCS INC.

(MYND)
SummaryQuotesChartsNewsCalendarCompanyFinancials 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

MYND Life Sciences Announces Depression Biomarker Diagnostic Program

06/01/2021 | 07:17am EST

MYND Lifesciencs Inc. announced the expansion of the intellectual property portfolio to more precisely diagnose and then monitor the treatment regime for patients with Major Depressive Disorder (MDD) and other diseases of inflammation. Stable Isotope Standards and Capture by Anti-Peptide Antibodies (SISCAPA) is a patented sample preparation methods platform for diagnostics that improves the performance of mass spectrometry (MS) for measurement of pre-selected protein targets. It is a method that will assist the research team with the proprietary panel of biomarkers aimed at diagnosing and monitoring Major Depressive Disorder. MYND aims to commercialize this panel by the first quarter of 2022. MYND continues to execute upon its multi-phase drug development strategy to create a novel drug discovery platform and research on the potential efficacy of psychedelic molecules to address unmet mental health needs; dosing control for enhanced drug delivery; and a potential novel diagnostic and treatment regimen.


ę S&P Capital IQ 2021
All news about MYND LIFESCIENCS INC.
11/18MYND Diagnostics Commences Clinical Research on Multiple Sclerosis Biomarker Test
AQ
11/18MYND Diagnostics Inc. Commences Clinical Research on Multiple Sclerosis Biomarker Test
CI
10/28MYND Lifesciencs Inc. Announces Board and Audit Committee Changes
CI
10/27MYND Life Sciences Signs Agreement to Acquire Rights for the Use of Psychedelics to Tre..
CI
10/18KCSA Psychedelics Virtual Investor Conference Presentations Available for On-Demand Vie..
AQ
10/11KCSA Psychedelics Virtual Investor Conference Agenda Announced for October 13th & 14th
AQ
10/07MYND Life Sciences Announces Diagnostic Division with Formation of Wholly-Owned Subsidi..
CI
09/29MYND LIFE SCIENCES INC : . Announces RSU Grant
AQ
09/09MYND Lifesciencs Inc. announced that it has received CAD 2.7 million in funding
CI
08/26MYND LIFESCIENCS : Life Sciences Announces $3 Million Convertible Debenture Unit Offering
AQ
More news
Financials
Sales 2020 - - -
Net income 2020 -0,00 M -0,00 M -0,00 M
Net Debt 2020 - - -
P/E ratio 2020 -
Yield 2020 -
Capitalization 16,1 M 12,6 M 12,6 M
Capi. / Sales 2019 -
Capi. / Sales 2020 -
Nbr of Employees 10
Free-Float -
Chart MYND LIFESCIENCS INC.
Duration : Period :
MYND Lifesciencs Inc. Technical Analysis Chart | MYND | CA62857B1094 | MarketScreener
Income Statement Evolution
Managers and Directors
Lyle Oberg Chief Executive Officer & Director
Paul Ciullo Chief Financial Officer & Secretary
Wilfred A. Jefferies Chairman & Chief Science Officer
Jordan Cleland Chief Operating Officer
John Campbell Independent Director